(Adnkronos) - “Rispetto alle terapie iniettive, finalmente abbiamo una piccola molecola che può essere assunta per bocca una volta al giorno e che induce la guarigione delle placche psoriasiche in più del 60% dei pazienti, finché si continua con l’assunzione”. A dirlo il professore ordinario di Dermatologia e direttore dell’Uoc di Dermatologia presso Irccs Istituto clinico Humanitas di Rozzano (Mi) Antonio Costanzo, durante la conferenza stampa con cui Bristol Myers Squibb ha annunciato il via libera da parte di Aifa alla rimborsabilità di deucravacitinib per il trattamento della psoriasi da moderata a severa.
Category
🗞
NewsTranscript
00:00Finally, we have a therapeutic novelty. Most of the effective therapies for psoriasis
00:12have been injective therapies, monoclonal antibodies, so-called biological drugs. Finally,
00:17a small molecule arrives that can be taken by mouth once a day, which interferes
00:24precisely with the mechanisms that lead to the development of plaques. And how does it work?
00:29It binds to a protein that is inside the cells and that has the task of signaling inflammation.
00:35So, by blocking this protein, it blocks the inflammation signal in the skin of our patients.
00:42And what happens? It happens that over the course of weeks, the patient sees his skin improve
00:49and, in concomitance, he sees his quality of life improve, because the pluritus disappears,
00:55the visible plaques disappear. This molecule, which has finally been approved and also
01:02reimbursed in Italy through the National Health Service, has been tested in clinical studies
01:09against another oral molecule, called Premilast, which has worked less. So,
01:15Deucravacitinib works about 20-30% more than Premilast. It induces the healing of
01:25psoriasis plaques in more than 60% of our patients. So, it is used for those patients
01:32who have a severe moderate disease, failure or contraindication of conventional therapies
01:40such as cyclosporine and methotrexate, and on a large number of patients affected by this disease.
01:48So far, the data we have tell us that as long as you take Deucravacitinib,
01:54as long as you take this compress every day, psoriasis remains under control.
01:59With suspension, psoriasis can return, of course, because it is a chronic disease,
02:04on a genetic basis, but it returns very slowly, so there is always time to restart the therapy.
02:12The indication, at the moment, is to take it chronically.